VEGFA and diabetic macular edema: Despite the recent introduction of antivascular endothelial growth factor (VEGF) therapies against vision-threatening diabetic macular edema, which has remarkably improved its prognosis, DR is still one of the most disabling sequelae of diabetes and a heavy socioeconomic burden.